Recruiting

Observational Study

Sponsor:

Dana-Farber Cancer Institute

Code:

NCT04028531

Conditions

Chronic Lymphocytic Leukemia

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Study Details

Brief summary:

The purpose of this study is to collect human Chronic Lymphocytic Leukemia tissue samples and medical information, in order to find out more about the causes and biology of chronic lymphocytic leukemia.

Conditions

Chronic Lymphocytic Leukemia

Study ID

NCT04028531

Start date

Sep 29, 1999

Status verified date

Apr, 2026

Completion date

Sep 29, 2032

Anticipated

Primary completion date

Sep 29, 2030

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Inclusion Criteria:

  • New and existing patients seen for treatment of monoclonal B-cell lymphocytosis
  • Any low grade lymphoproliferative disorder
  • Chronic Lymphocytic Leukemia in the Dana Farber Cancer Institute Hematologic Oncology Clinic or elsewhere

Exclusion Criteria:

\-

Study Design

Enrollment

2750 participants

Anticipated

Interventions and Outcome Measures

Arms

Sample Collection

  • Blood tests required for assessment
  • Specimens and data will also be collected from outside sites
  • Clinical data from patients with Chronic Lymphocytic Leukemia will be gathered into a database at Dana Farber Cancer Institute

Primary outcome measure

  • Incidence of novel genomic prognostic markers in Chronic Lymphocytic Leukemia [ Time Frame: 20 years ]

Central Contacts and Locations

Central contacts

Jennifer Brown, MD, PhD

617-582-8437Jennifer_brown@dfci.harvard.edu

Locations

Dana Farber Cancer Institute

Recruiting

Boston, Massachusetts, United States, 02115

Contacts

Jennifer Brown, MD, PhD

617-582-8437Jennifer_brown@dfci.harvard.edu

Principal Investigator:

Jennifer Brown, MD, PhD

More Information

Sponsor

Dana-Farber Cancer Institute

Last update posted

Apr 24, 2026

Last verified

Apr, 2026

Keywords

  • Chronic Lymphocytic Leukemia

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-08. This information was provided to ClinicalTrials.gov by Dana-Farber Cancer Institute on 2026-04-24.